Home
/
Records
/
Untitled Letter
/
HomeRx

UNTITLED LETTER

•HomeRx•September 16, 2021

FDA UNTITLED_LETTER - HomeRx - September 16, 2021

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Record Details

This UNTITLED LETTER record concerns HomeRx, with an inspection on September 16, 2021.

Company: HomeRx
Inspection Date: September 16, 2021
Person: Diana Amador-Toro (District Director)

Open in Dashboard

ID · 67b22c1b-f0c5-4df5-81d9-e9d5271f5acd

Violation Codes7

FD&C Act 501(a)(2)(B)FD&C Act 301(a)FD&C Act 502(f)(1)FD&C Act 501(a)(2)(A)FD&C Act 50521 U.S.C. 331(a)21 U.S.C. 331(k)

Full citation text and observation details available on the Dashboard.

Global Key Solutions

Regulatory Data Transformed

Contact

New York Office:

370 Jay Street 7th Floor

Brooklyn, NY 11201

Scranton Office:

Scranton Enterprise Center, Suite 217

201 Lackawanna Avenue

Scranton, PA, 18503

🇺🇸+1 917-789-5099

🇪🇺+48 532-447-507

[email protected]

Quick Links

KeyPedia™ Lite

Legal & Ethics

©2026, Global Key Solutions All rights reserved.

FDA UNTITLED_LETTER - HomeRx - September 16, 2021 | Global Key Solutions